The Rs 3000-crore Zydus Group's listed entity Cadila Healthcare has finally secured nod from US FDA for Topiramate capsules in multiple strengths.

The drug, which is the generic version of Ortho McNeil's Topamax capsules, is indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures.

Topiramate Tablets are available as 25 mg, 50 mg, 100 mg, and 200 mg round tablets for oral administration. The drug had total sale of $58 million in US market for the 12 month ended June 2009.

Karvy Stock Broking has recommended a market performer rating on Cadila Healthcare with price target of Rs 600, in its report dated October 15, 2009. The shares of Cadila Healthcare closed on Friday at Rs 550 on BSE. The scrip touched an intraday high and low of Rs 553 and Rs 541 respectively.